Skip to content
Manufacturing, Medical Health Aged Care

Iconic Australian Dermatological Skincare Company Celebrates 30 Years of Success in the Middle East

Ego Pharmaceuticals 2 mins read

Ego Pharmaceuticals, a leading Australian dermatological skincare company is proudly celebrating two major milestones this year, with 70 years of operations globally and 30 years in the Middle East.

Ego Pharmaceuticals became the first Australian skincare company to venture into the Middle East, despite being relatively unknown at the time. Over three decades, Ego has solidified its presence in the region, which currently contributes to 50% of its total exports and 25% of its overall global business.

With a workforce of 110 professionals across 7 Middle Eastern countries, Ego Pharmaceuticals is moving to a new MEA support centre in central Dubai this September and expanding operations in Saudi Arabia later in the year.

Alan Oppenheim, Managing Director, said of the company's journey: "Ego's entry into the Middle East was a significant leap for our small company. Looking back on the collective efforts of our teams in Australia and the Middle East over these three decades fills me with immense pride. Knowing that our products have played a role in improving the lives of those in the Middle East dealing with chronic skin conditions is truly gratifying. We are now a leading Australian company with sustainable operations in a vibrant and growing Middle East market."

Ego Pharmaceuticals' dedication to the Middle East has resulted in consistent growth. From its initial entry into the UAE in 1993, the company expanded its presence into Bahrain, Jordan, Saudi Arabia, Kuwait, Qatar, and Oman. Recognitions include awards at the Australian Export Awards for Health and Biotechnology in 2015, as well as the Manufacturing Export Award and Australian Exporter of the Year title in 2017.

Ego's thriving export success to the Middle East has led to significant investments in its Australian operations, based in Melbourne, including current projects to upgrade to its manufacturing facility and the expansion of its global distribution centre. These initiatives are expected to increase production capacity by 100% and create 90 new jobs.

For media inquiries, please contact:

Marketing.MiddleEast@egopharm.com

 

 


About us:

About Ego Pharmaceuticals: Proudly Australian owned and made, Ego Pharmaceuticals has led the way in the development, manufacture and marketing of innovative dermatological products for 70 years. Today the company produces over 120 different products including the QV Skincare range, DermAid, MOOV and SunSense. Ego’s mission is to exist for people who want healthy looking skin by being the specialist in skincare, backed by science. Visit us   www.egopharm.com/middle-east


Contact details:

marketing.middleeast@egopharm.com

Media

More from this category

  • Government Federal, Medical Health Aged Care
  • 22/03/2025
  • 09:16
Consumers Health Forum

Half a million Australians missing out on cheaper medicines due to outdated systems

Half a million Australians missing out on cheaper medicines due to outdated systems Nearly half a million eligible Australians are missing out on cheaper medicines due to an outdated manual tracking system that should be automated. The Consumers Health Forum of Australia (CHF) is calling for urgent automation of the PBS Safety Net system after it was revealed 495,865 people who qualified for the benefits in 2024 missed out due to the current paper-based tracking system. This means almost half a million people are paying more than they should for essential medicine, paying full price for medication when they should…

  • Medical Health Aged Care, Science
  • 22/03/2025
  • 08:00
UNSW Sydney

AI-powered breath test could detect silicosis early: study

The new test for silicosis has shown promise in an early study, and is now being analysed in larger cohorts. A new diagnostic tool developed by physicians and scientists fromUNSW Sydney that analyses a person’s breath for signs of silicosis has the potential to catch the disease earlier rather than wait for irreversible lung damage to appear. In a study published today in the Journal of Breath Research by Professor William Alexander Donald and Conjoint Professor Deborah Yates, the researchers describe a rapid, AI-powered breath test that could transform the way silicosis is diagnosed. The test combines mass spectrometry –…

  • Medical Health Aged Care
  • 22/03/2025
  • 06:00
Dementia Australia

Join us today for Forster-Tuncurry Memory Walk & Jog

What: Dementia Australia’s Forster-Tuncurry Memory Walk & Jog    When: Saturday, 22 March from 8:00am   Who: More than 110 locals participating on the day. People who have been impacted by dementia, their family, friends and carers.   Where: John Wright Park, Tuncurry   Dementia Australia spokespeople and local residents are available for interview. Photos and video of previous Memory Walk & Jog events for publication are available for use. For more information visit: www.memorywalk.com.au Dementia Australia is the source of trusted information, education and services for the estimated more than 433,300 Australians living with dementia, and the more than 1.7 million…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.